188 related articles for article (PubMed ID: 31678282)
1. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
[TBL] [Abstract][Full Text] [Related]
2. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
Ramezani S; Vousooghi N; Ramezani Kapourchali F; Joghataei MT
Apoptosis; 2017 Aug; 22(8):1025-1034. PubMed ID: 28616662
[TBL] [Abstract][Full Text] [Related]
3. Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells.
Ramezani S; Vousooghi N; Kapourchali FR; Hadjighasem M; Hayat P; Amini N; Joghataei MT
Life Sci; 2017 Mar; 173():11-19. PubMed ID: 28202289
[TBL] [Abstract][Full Text] [Related]
4. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Goldhoff P; Warrington NM; Limbrick DD; Hope A; Woerner BM; Jackson E; Perry A; Piwnica-Worms D; Rubin JB
Clin Cancer Res; 2008 Dec; 14(23):7717-25. PubMed ID: 19047098
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
7. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
8. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
Liang J; Piao Y; Henry V; Tiao N; de Groot JF
Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
[TBL] [Abstract][Full Text] [Related]
9. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.
Moon EY; Lee GH; Lee MS; Kim HM; Lee JW
Life Sci; 2012 Feb; 90(9-10):373-80. PubMed ID: 22227470
[TBL] [Abstract][Full Text] [Related]
12. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
13. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
15. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
16. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
[TBL] [Abstract][Full Text] [Related]
17. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Li Q; Peng Y; Fan L; Xu H; He P; Cao S; Li J; Chen T; Ruan W; Chen G
Biomed Pharmacother; 2018 Mar; 99():947-955. PubMed ID: 29710495
[TBL] [Abstract][Full Text] [Related]
19. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
20. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
